CR10748A - Compuesto de indol - Google Patents

Compuesto de indol

Info

Publication number
CR10748A
CR10748A CR10748A CR10748A CR10748A CR 10748 A CR10748 A CR 10748A CR 10748 A CR10748 A CR 10748A CR 10748 A CR10748 A CR 10748A CR 10748 A CR10748 A CR 10748A
Authority
CR
Costa Rica
Prior art keywords
indol compound
indol
compound
agent
glucocin
Prior art date
Application number
CR10748A
Other languages
English (en)
Spanish (es)
Inventor
Yasuma Tsuneo
Ujikawa Osamu
Itoh Masahiro
Aoki Kazuko
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39010108&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10748(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR10748A publication Critical patent/CR10748A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR10748A 2006-10-19 2009-04-24 Compuesto de indol CR10748A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006285551 2006-10-19

Publications (1)

Publication Number Publication Date
CR10748A true CR10748A (es) 2009-05-20

Family

ID=39010108

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10748A CR10748A (es) 2006-10-19 2009-04-24 Compuesto de indol

Country Status (26)

Country Link
US (4) US8410087B2 (enExample)
EP (2) EP2074119A1 (enExample)
JP (1) JP5260507B2 (enExample)
KR (1) KR101444486B1 (enExample)
CN (1) CN101573357B (enExample)
AU (1) AU2007310064B2 (enExample)
BR (1) BRPI0717722A2 (enExample)
CA (1) CA2666973C (enExample)
CL (1) CL2008001017A1 (enExample)
CR (1) CR10748A (enExample)
EC (1) ECSP099330A (enExample)
GE (1) GEP20115241B (enExample)
IL (1) IL198154A (enExample)
MA (1) MA30890B1 (enExample)
ME (1) ME00681B (enExample)
MX (1) MX2009003972A (enExample)
MY (1) MY158052A (enExample)
NO (1) NO20091948L (enExample)
NZ (1) NZ576570A (enExample)
PE (1) PE20090884A1 (enExample)
RU (1) RU2454415C9 (enExample)
TN (1) TN2009000129A1 (enExample)
TW (1) TWI460176B (enExample)
UA (1) UA97257C2 (enExample)
WO (1) WO2008050821A1 (enExample)
ZA (1) ZA200902585B (enExample)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445679B2 (en) * 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素5員複素環化合物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009025477A1 (en) 2007-08-17 2009-02-26 Lg Life Sciences Ltd. Indole compounds as an inhibitor of cellular necrosis
US20100267708A1 (en) * 2007-12-20 2010-10-21 Lg Life Sciences Ltd. Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
US20100291533A1 (en) * 2008-01-04 2010-11-18 Soon Ha Kim Indole and indazole derivatives having a cell-, tissue- and organ-preserving effect
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DK2276760T3 (da) 2008-04-10 2014-05-26 Takeda Pharmaceutical Kondenserede ringforbindelser og anvendelse deraf
US8349886B2 (en) * 2008-04-16 2013-01-08 Takeda Pharmaceutical Company Limited Nitrogenated 5-membered heterocyclic compound
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
JP5597200B2 (ja) * 2008-08-18 2014-10-01 プロメガ コーポレイション ルミネッセンスを生じる化合物およびチトクロムp4503a酵素を検出するための方法
AR073380A1 (es) 2008-09-25 2010-11-03 Takeda Pharmaceutical Composicion farmaceutica solida. comprimido multicapa
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC COMPOUND
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
WO2010117085A1 (en) * 2009-04-09 2010-10-14 Banyu Pharmaceutical Co.,Ltd. Aryl indole derivatives
EP2440541A1 (en) 2009-06-09 2012-04-18 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
MX2012001284A (es) 2009-07-28 2012-03-26 Takeda Pharmaceutical Tableta.
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
MA34245B1 (fr) 2010-04-27 2013-05-02 Takeda Pharmaceutcal Company Ltd Dérivés de composés bicycliques et leur utilisation en tant qu'inhibiteurs de l'acc.
EA022094B1 (ru) 2010-06-16 2015-10-30 Такеда Фармасьютикал Компани Лимитед Кристаллическая форма амидного соединения
WO2011159781A2 (en) * 2010-06-17 2011-12-22 Senomyx, Inc. Bitter taste modulators
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2617726A4 (en) 2010-09-17 2014-05-14 Takeda Pharmaceutical DIABETES THERAPEUTIC
EA201390794A1 (ru) 2010-11-30 2013-11-29 Такеда Фармасьютикал Компани Лимитед Бициклическое соединение
BR112013020634A2 (pt) 2011-02-17 2016-10-25 Takeda Pharmaceutical método para produzir uma forma opticamente ativa de um composto, sal, complexo de rutênio, composto, e, cristal
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013057944A1 (ja) * 2011-10-19 2013-04-25 興和株式会社 新規なスピロインドリン化合物、及びそれを含有する医薬
EP2772485A4 (en) 2011-10-24 2015-06-10 Takeda Pharmaceutical BICYCLIC CONNECTION
EP2802571A1 (en) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
EP2816032A4 (en) 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
US20150011549A1 (en) 2012-02-15 2015-01-08 Takeda Pharmaceutical Company Limited Tablet
CN104254525B (zh) 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
EP2836482B1 (en) 2012-04-10 2019-12-25 The Regents of The University of California Compositions and methods for treating cancer
US9440987B2 (en) 2012-05-10 2016-09-13 Takeda Pharmaceutical Company Limited Aromatic ring compound
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
CN104519874B (zh) 2012-06-05 2018-08-03 武田药品工业株式会社 固体制剂
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
WO2014085486A2 (en) 2012-11-30 2014-06-05 Waters Technologies Corporation Methods and apparatus for the analysis of vitamin d metabolites
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
TW201536767A (zh) 2013-07-09 2015-10-01 Takeda Pharmaceutical 雜環化合物
HRP20181011T1 (hr) 2013-08-09 2018-08-24 Takeda Pharmaceutical Company Limited Aromatski spoj
WO2015026172A1 (ko) * 2013-08-22 2015-02-26 주식회사 엘지생명과학 세포괴사 저해제로서의 인돌아미드 화합물
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN104098498A (zh) * 2014-07-30 2014-10-15 天津市斯芬克司药物研发有限公司 一种吲唑类化合物及其制备方法
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
CN110719903A (zh) 2017-03-31 2020-01-21 武田药品工业株式会社 芳族环化合物
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EA202092269A1 (ru) 2018-03-23 2020-12-14 Кармот Терапьютикс, Инк. Модуляторы сопряженных с g-белком рецепторов
TW202024028A (zh) 2018-08-27 2020-07-01 日商思可海雅藥品股份有限公司 苯甲酸酯化合物
JP7511548B2 (ja) 2018-09-24 2024-07-05 武田薬品工業株式会社 Gip受容体アゴニストペプチド化合物及びその使用
US12122815B2 (en) 2018-09-24 2024-10-22 Takeda Pharmaceutical Company Limited GIP receptor agonist peptide compounds and uses thereof
CN109250963B (zh) * 2018-09-29 2021-07-16 福建省昊立建设工程有限公司 一种复合增韧混凝土及其制备方法
PH12022552056A1 (en) 2020-02-07 2024-02-12 Gasherbrum Bio Inc Heterocyclic glp-1 agonists
PE20221727A1 (es) 2020-03-25 2022-11-04 Takeda Pharmaceuticals Co Dosificacion qw de compuestos peptidicos agonistas del receptor de gip y sus usos
BR112022019114A2 (pt) 2020-03-25 2023-02-14 Takeda Pharmaceuticals Co Dosagem qd de compostos peptídicos agonistas do receptor de gip e usos dos mesmos
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
PE20240890A1 (es) 2021-05-13 2024-04-24 Carmot Therapeutics Inc Moduladores de los receptores acoplados a proteinas g
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
JP2025510741A (ja) 2022-03-21 2025-04-15 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式glp-1アゴニスト
CN119255988A (zh) 2022-04-14 2025-01-03 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
EP4638455A1 (en) 2022-12-22 2025-10-29 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN120957993A (zh) 2023-02-16 2025-11-14 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2025006921A1 (en) 2023-06-30 2025-01-02 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
TW202519220A (zh) 2023-07-13 2025-05-16 美商雅空嘉閣生物公司 化合物、組合物及方法
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
US20250188081A1 (en) * 2023-12-08 2025-06-12 Shaman Pharma, LLC Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2656610B1 (fr) * 1989-12-29 1992-05-07 Sanofi Sa Derives d'amino-2 phenyl-4 thiazole, leur procede de preparation et leur application therapeutique.
KR0174752B1 (ko) * 1993-09-10 1999-02-01 나이토 하루오 이환식 헤테로환 함유 술폰아미드 유도체 및 그 제조방법
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
CA2322162A1 (en) * 1998-02-25 1999-09-02 Genetics Institute, Llc Inhibitors of phospholipase enzymes
JP4007743B2 (ja) 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
GB0003636D0 (en) * 2000-02-16 2000-04-05 Smithkline Beecham Plc Novel compounds
US6930185B2 (en) 2000-04-28 2005-08-16 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
MXPA05003391A (es) 2002-10-03 2005-06-22 Hoffmann La Roche Indol-3-carboxamidas como activadores de glucocinasa.
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
US7498445B2 (en) * 2004-05-05 2009-03-03 Renopharm Ltd. Thiazole-based nitric oxide donors capable of releasing two or more nitric oxide molecules and uses thereof
EP1632491A1 (en) * 2004-08-30 2006-03-08 Laboratorios Del Dr. Esteve, S.A. Substituted indole compounds and their use as 5-HT6 receptor modulators
CA2605778A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
WO2007037534A1 (ja) 2005-09-30 2007-04-05 Banyu Pharmaceutical Co., Ltd. 2-へテロアリール置換インドール誘導体
DK2188291T3 (da) * 2007-08-14 2013-01-07 Bayer Ip Gmbh Fusionerede bicykliske pyrimidiner
PA8793301A1 (es) * 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
JO2784B1 (en) * 2007-10-18 2014-03-15 شركة جانسين فارماسوتيكا ان. في 5,3,1 - Triazole substitute derivative
ES2424023T3 (es) * 2007-10-18 2013-09-26 Janssen Pharmaceutica N.V. 1,2,4-triazoles trisustituidos

Also Published As

Publication number Publication date
JP2010506825A (ja) 2010-03-04
MEP11809A (en) 2011-12-20
EP2074119A1 (en) 2009-07-01
ECSP099330A (es) 2009-06-30
CA2666973A1 (en) 2008-05-02
JP5260507B2 (ja) 2013-08-14
IL198154A0 (en) 2009-12-24
MY158052A (en) 2016-08-30
KR101444486B1 (ko) 2014-09-24
EP2508524A3 (en) 2012-10-24
RU2009118602A (ru) 2010-11-27
NZ576570A (en) 2010-11-26
UA97257C2 (en) 2012-01-25
NO20091948L (no) 2009-07-13
WO2008050821A1 (en) 2008-05-02
AU2007310064B2 (en) 2013-03-28
US20090286975A1 (en) 2009-11-19
BRPI0717722A2 (pt) 2013-10-29
US20080096877A1 (en) 2008-04-24
RU2454415C2 (ru) 2012-06-27
US20100144702A1 (en) 2010-06-10
CA2666973C (en) 2015-03-31
CL2008001017A1 (es) 2009-04-24
TW200825071A (en) 2008-06-16
TN2009000129A1 (en) 2010-10-18
GEP20115241B (en) 2011-06-10
MA30890B1 (fr) 2009-11-02
CN101573357A (zh) 2009-11-04
MX2009003972A (es) 2009-04-27
US7652133B2 (en) 2010-01-26
US7718798B2 (en) 2010-05-18
IL198154A (en) 2014-08-31
TWI460176B (zh) 2014-11-11
US20100137610A1 (en) 2010-06-03
US7777047B2 (en) 2010-08-17
US8410087B2 (en) 2013-04-02
ZA200902585B (en) 2010-09-29
PE20090884A1 (es) 2009-08-05
AU2007310064A1 (en) 2008-05-02
AU2007310064A2 (en) 2009-06-04
EP2508524A2 (en) 2012-10-10
ME00681B (me) 2011-12-20
CN101573357B (zh) 2013-01-23
KR20090068292A (ko) 2009-06-25
RU2454415C9 (ru) 2013-02-27

Similar Documents

Publication Publication Date Title
CR10748A (es) Compuesto de indol
MY153915A (en) Organic compounds
MA32508B1 (fr) Composes organiques
MX2009006481A (es) Derivados de imidazol 1-sustituidos, y su uso como inhibidores de la sintasa de aldosterona.
EA201001847A1 (ru) Соединения и композиции, применяемые для лечения малярии
MX2011005934A (es) Compuestos organicos.
MX2009006536A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
EA201170349A1 (ru) Модуляторы mif
CL2009000650A1 (es) Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras
MX2010009736A (es) Compuesto heterociclico.
DOP2011000386A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
ECSP099618A (es) Compuestos anulares fusionados como agonistas parciales de ppar-gamma
CL2008003116A1 (es) Compuestos heterocíclicos bicíclicos; composición farmacéutica que comprende a dichos compuestos; y su uso en el tratamiento o prevención de enfermedades tales como diabetes, obesidad, trastorno metabólico, enfermedad cardiovascular entre otras.
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
DE602007010664D1 (de) P53 aktivierende benzoylharnstoff- und benzoylthioharnstoff-verbindungen
EA201101477A1 (ru) Органические соединения и их применение
CR11741A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida
CL2007002890A1 (es) Compuestos derivados de 2-piridincarboxamida, activador de glucosinasa; composicion farmaceutica; y uso del compuesto para el tratamiento de diabetes o la obesidad.
EA201101116A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
EA201270590A1 (ru) Ингибиторы акт
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
CR11423A (es) NUEVOS INHIBIDORES DE sEH Y SU USO
TNSN08496A1 (en) Aminothiazoles and their uses